Stay updated on SubQ Efgartigimod in CIDP Clinical Trial
Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page
- Check3 days agoChange DetectedPublications section now includes the Lancet Neurology ADHERE publication citation. The previous citation entry was removed.SummaryDifference0.0%

- Check10 days agoChange DetectedRevision: v3.4.2 appears as a minor metadata update with no impact on study data or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoChange DetectedRevision metadata updated: v3.4.1 added and v3.4.0 removed.SummaryDifference0.0%

- Check32 days agoChange DetectedShow glossary is now displayed and the page revision is updated to v3.4.0, replacing the prior wording 'Last Update Submitted that met QC Criteria' from v3.3.4. The No FEAR Act data label was changed to 'No FEAR Act data' (To avoid being alerted by small changes, set an alert condition by clicking below.)SummaryDifference0.1%

- Check39 days agoChange DetectedRevision entry updated to v3.3.4; the previous v3.3.3 revision was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check67 days agoChange DetectedAdded a Locations section listing study sites by state. Several state location entries were removed and the HHS Vulnerability Disclosure section was deleted.SummaryDifference0.8%

Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.